1. Home >
  2. M&A >
  3. Growth Capital >
  4. United States >
  5. Massachusetts >
  6. CK Life Sciences Int’l. Invests In TransCode

Investment Summary

CK Life Sciences Int’l. Invests In TransCode

On October 8, 2025, CK Life Sciences Int’l. invested in life science company TransCode

Investment Highlights
  • This is CK Life Sciences Int’l.’s 1st transaction in the Life Science sector.
  • This is CK Life Sciences Int’l.’s 2nd transaction in the United States.
  • This is CK Life Sciences Int’l.’s 1st transaction in Massachusetts.

Investment Summary
Date 2025-10-08
Target TransCode
Sector Life Science
Investor(s) CK Life Sciences Int’l.
Deal Type Growth Capital

Target

TransCode

Newton, Massachusetts, United States
TransCode is a clinical-stage oncology company focused on treating metastatic disease. The Company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. TransCode lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, it has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers. TransCode is based in Newton, Massachusetts.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

CK Life Sciences Int’l.

Tai Po, China
Category Company
Founded 1999
Sector Life Science
Employees1,935
Revenue 5.5B HKD (2024)
DESCRIPTION

CK Life Sciences Int’l. is an entity that bears the mission of improving the quality of life, CK Life Sciences is engaged in the business of research and development, commercialisation, marketing and sale of health and agriculture-related products. CK Life Sciences Int’l was founded in 1999 and is based in Tai Po, China.

DEAL STATS #
Overall 6 of 6
Sector: Life Science M&A 1 of 1
Type: Growth Capital M&A Deals 1 of 1
State: Massachusetts M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2025 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2025-10-08 Polynoma

San Diego, California, United States

Polynoma is a U.S. immuno-oncology-focused biopharmaceutical company using its lead asset, a novel polyvalent shed antigen vaccine, seviprotimut-L, for the prevention of recurrence of melanoma. Polynoma is based in San Diego, California.

Sell -
Mergr

Solution for

Product

Company

Legal